摘要 |
The use of at least one ligand specific for RXR receptors in the preparation of a pharmaceutical composition for systemic administration, which increases the modulating activity in cell proliferation and/or differentiation of a ligand of at least one member of the steroidal/thyroidal receptor super-family, other than a specific ligand for RXR receptors, and which can hetero-dimerise with RXRs applied topically, is new. |